Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + T-DM1 in HER2+ PD-L1+ Advanced Breast Cancer (KATE3)
NCT04740918Phase 3Terminated
- Sponsor
- Roche
- Start
- Jun 2021
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of atezolizumab in breast cancer, sponsored by Roche. Started Jun 2021; status: terminated.
02
Drugs
atezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04740918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04740918.